Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 418

1.

Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis.

Mihai DP, Nitulescu GM, Ion GND, Ciotu CI, Chirita C, Negres S.

Pharmaceutics. 2019 Sep 2;11(9). pii: E446. doi: 10.3390/pharmaceutics11090446.

2.

The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study.

Wang Y, Bernanke J, Peterson BS, McGrath P, Stewart J, Chen Y, Lee S, Wall M, Bastidas V, Hong S, Rutherford BR, Hellerstein DJ, Posner J.

Lancet Psychiatry. 2019 Aug;6(8):667-674. doi: 10.1016/S2215-0366(19)30179-8. Epub 2019 Jun 24.

PMID:
31248841
3.

Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis.

Tran BX, Ha GH, Vu GT, Nguyen LH, Latkin CA, Nathan K, McIntyre RS, Ho CS, Tam WW, Ho RC.

Int J Environ Res Public Health. 2019 Jun 26;16(13). pii: E2255. doi: 10.3390/ijerph16132255.

4.

Pharmacist-led medication non-adherence intervention: reducing the economic burden placed on the Australian health care system.

Cutler RL, Torres-Robles A, Wiecek E, Drake B, Van der Linden N, Benrimoj SIC, Garcia-Cardenas V.

Patient Prefer Adherence. 2019 May 23;13:853-862. doi: 10.2147/PPA.S191482. eCollection 2019.

5.

Frequency of Sexual Dysfunction in Patients Treated with Desvenlafaxine: A Prospective Naturalistic Study.

Montejo AL, Becker J, Bueno G, Fernández-Ovejero R, Gallego MT, González N, Juanes A, Montejo L, Pérez-Urdániz A, Prieto N, Villegas JL.

J Clin Med. 2019 May 21;8(5). pii: E719. doi: 10.3390/jcm8050719.

6.

Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis.

Shinohara K, Efthimiou O, Ostinelli EG, Tomlinson A, Geddes JR, Nierenberg AA, Ruhe HG, Furukawa TA, Cipriani A.

BMJ Open. 2019 May 19;9(5):e027574. doi: 10.1136/bmjopen-2018-027574.

7.

A Review of Novel Antidepressants: A Guide for Clinicians.

Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S.

Cureus. 2019 Mar 6;11(3):e4185. doi: 10.7759/cureus.4185. Review.

8.

Managing vasomotor symptoms in women after cancer.

Pinkerton JV, Santen RJ.

Climacteric. 2019 May 13:1-9. doi: 10.1080/13697137.2019.1600501. [Epub ahead of print]

PMID:
31081391
9.
10.

Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis.

Tomlinson A, Efthimiou O, Boaden K, New E, Mather S, Salanti G, Imai H, Ogawa Y, Tajika A, Kishimoto S, Kikuchi S, Chevance A, Furukawa TA, Cipriani A.

Evid Based Ment Health. 2019 May;22(2):61-66. doi: 10.1136/ebmental-2019-300087. Epub 2019 Apr 17.

PMID:
30996028
11.
12.

Using Dispensing Data to Evaluate Adherence Implementation Rates in Community Pharmacy.

Torres-Robles A, Wiecek E, Cutler R, Drake B, Benrimoj SI, Fernandez-Llimos F, Garcia-Cardenas V.

Front Pharmacol. 2019 Feb 26;10:130. doi: 10.3389/fphar.2019.00130. eCollection 2019.

13.

Serotonin and Norepinephrine Reuptake Inhibitors.

Shelton RC.

Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164.

PMID:
30838456
14.

Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder.

Suh JS, Minuzzi L, Cudney LE, Maich W, Eltayebani M, Soares CN, Frey BN.

Neuroreport. 2019 Mar 20;30(5):378-382. doi: 10.1097/WNR.0000000000001211.

PMID:
30741785
15.

Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine.

Wu L, Gerdts EA, Alam A.

Prim Care Companion CNS Disord. 2019 Jan 10;21(1). pii: 18l02362. doi: 10.4088/PCC.18l02362. No abstract available.

16.

Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine.

Alonso-Prieto E, Rubino C, Lucey M, Evans VC, Tam EM, Woo C, Iverson GL, Chakrabarty T, Yatham LN, Lam RW.

Psychiatry Res. 2019 Feb;272:144-148. doi: 10.1016/j.psychres.2018.12.062. Epub 2018 Dec 10.

PMID:
30583256
17.

Fungal biodegradation of the N-nitrosodimethylamine precursors venlafaxine and O-desmethylvenlafaxine in water.

Llorca M, Castellet-Rovira F, Farré MJ, Jaén-Gil A, Martínez-Alonso M, Rodríguez-Mozaz S, Sarrà M, Barceló D.

Environ Pollut. 2019 Mar;246:346-356. doi: 10.1016/j.envpol.2018.12.008. Epub 2018 Dec 7.

PMID:
30577003
18.

Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine.

Garakani A.

Prim Care Companion CNS Disord. 2018 Dec 13;20(6). pii: 18l02316. doi: 10.4088/PCC.18l02316. No abstract available.

19.

Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study.

Luo Y, Chaimani A, Kataoka Y, Ostinelli EG, Ogawa Y, Cipriani A, Salanti G, Furukawa TA.

BMJ Open. 2018 Dec 9;8(12):e023222. doi: 10.1136/bmjopen-2018-023222.

20.

Desvenlafaxine .

Naseeruddin R, Marwaha R.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2018 Nov 28.

Supplemental Content

Loading ...
Support Center